Immunopathological and molecular basis of functional dyspepsia and current therapeutic approaches

Mounika Addula, Victoria E.D. Wilson, Savio Reddymasu, Devendra K. Agrawal

Research output: Contribution to journalReview article

Abstract

Introduction: Functional dyspepsia (FD) is widespread with 20% prevalence worldwide and a significant economic burden due to health care cost and constraints on daily activities of patients. Despite extensive investigation, the underlying causes of dyspepsia in a majority of patients remain unknown. Common complaints include abdominal discomfort, pain, burning, nausea, early satiety, and bloating. Motor dysfunction of the gut was long considered a major cause, but recent investigations suggest immune-based pathophysiological and molecular events in the duodenum are more probable contributing factors. Areas Covered: Inflammatory mediators and immune cells including duodenal eosinophils, intraepithelial lymphocytes, and T-cells have been implicated in the underlying cause of disease process, as have genetic factors. In this article, we critically reviewed findings, identified gaps in knowledge and suggested future directions for further investigation to identify targets and develop better therapeutic approaches. Expert commentary: Impaired gastric accommodation, slow gastric emptying, and increased visceral sensitivity have long been thought of as main causal factors of FD. However, more recent identification of eosinophilic degranulation and recruitment of T cells that induce mild duodenal inflammation are giving rise to new insights into immune-mediated pathophysiology. These insights offer promising avenues to explore for immune-mediated therapy in the future.

Original languageEnglish (US)
Pages (from-to)831-840
Number of pages10
JournalExpert Review of Clinical Immunology
Volume14
Issue number10
DOIs
StatePublished - Oct 3 2018

Fingerprint

Dyspepsia
T-Lymphocytes
Gastric Emptying
Duodenum
Eosinophils
Health Care Costs
Nausea
Abdominal Pain
Stomach
Therapeutics
Economics
Lymphocytes
Inflammation

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Immunopathological and molecular basis of functional dyspepsia and current therapeutic approaches. / Addula, Mounika; Wilson, Victoria E.D.; Reddymasu, Savio; Agrawal, Devendra K.

In: Expert Review of Clinical Immunology, Vol. 14, No. 10, 03.10.2018, p. 831-840.

Research output: Contribution to journalReview article

Addula, Mounika ; Wilson, Victoria E.D. ; Reddymasu, Savio ; Agrawal, Devendra K. / Immunopathological and molecular basis of functional dyspepsia and current therapeutic approaches. In: Expert Review of Clinical Immunology. 2018 ; Vol. 14, No. 10. pp. 831-840.
@article{3c100aaec5b54e23b1614b226655b02d,
title = "Immunopathological and molecular basis of functional dyspepsia and current therapeutic approaches",
abstract = "Introduction: Functional dyspepsia (FD) is widespread with 20{\%} prevalence worldwide and a significant economic burden due to health care cost and constraints on daily activities of patients. Despite extensive investigation, the underlying causes of dyspepsia in a majority of patients remain unknown. Common complaints include abdominal discomfort, pain, burning, nausea, early satiety, and bloating. Motor dysfunction of the gut was long considered a major cause, but recent investigations suggest immune-based pathophysiological and molecular events in the duodenum are more probable contributing factors. Areas Covered: Inflammatory mediators and immune cells including duodenal eosinophils, intraepithelial lymphocytes, and T-cells have been implicated in the underlying cause of disease process, as have genetic factors. In this article, we critically reviewed findings, identified gaps in knowledge and suggested future directions for further investigation to identify targets and develop better therapeutic approaches. Expert commentary: Impaired gastric accommodation, slow gastric emptying, and increased visceral sensitivity have long been thought of as main causal factors of FD. However, more recent identification of eosinophilic degranulation and recruitment of T cells that induce mild duodenal inflammation are giving rise to new insights into immune-mediated pathophysiology. These insights offer promising avenues to explore for immune-mediated therapy in the future.",
author = "Mounika Addula and Wilson, {Victoria E.D.} and Savio Reddymasu and Agrawal, {Devendra K.}",
year = "2018",
month = "10",
day = "3",
doi = "10.1080/1744666X.2018.1524756",
language = "English (US)",
volume = "14",
pages = "831--840",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Immunopathological and molecular basis of functional dyspepsia and current therapeutic approaches

AU - Addula, Mounika

AU - Wilson, Victoria E.D.

AU - Reddymasu, Savio

AU - Agrawal, Devendra K.

PY - 2018/10/3

Y1 - 2018/10/3

N2 - Introduction: Functional dyspepsia (FD) is widespread with 20% prevalence worldwide and a significant economic burden due to health care cost and constraints on daily activities of patients. Despite extensive investigation, the underlying causes of dyspepsia in a majority of patients remain unknown. Common complaints include abdominal discomfort, pain, burning, nausea, early satiety, and bloating. Motor dysfunction of the gut was long considered a major cause, but recent investigations suggest immune-based pathophysiological and molecular events in the duodenum are more probable contributing factors. Areas Covered: Inflammatory mediators and immune cells including duodenal eosinophils, intraepithelial lymphocytes, and T-cells have been implicated in the underlying cause of disease process, as have genetic factors. In this article, we critically reviewed findings, identified gaps in knowledge and suggested future directions for further investigation to identify targets and develop better therapeutic approaches. Expert commentary: Impaired gastric accommodation, slow gastric emptying, and increased visceral sensitivity have long been thought of as main causal factors of FD. However, more recent identification of eosinophilic degranulation and recruitment of T cells that induce mild duodenal inflammation are giving rise to new insights into immune-mediated pathophysiology. These insights offer promising avenues to explore for immune-mediated therapy in the future.

AB - Introduction: Functional dyspepsia (FD) is widespread with 20% prevalence worldwide and a significant economic burden due to health care cost and constraints on daily activities of patients. Despite extensive investigation, the underlying causes of dyspepsia in a majority of patients remain unknown. Common complaints include abdominal discomfort, pain, burning, nausea, early satiety, and bloating. Motor dysfunction of the gut was long considered a major cause, but recent investigations suggest immune-based pathophysiological and molecular events in the duodenum are more probable contributing factors. Areas Covered: Inflammatory mediators and immune cells including duodenal eosinophils, intraepithelial lymphocytes, and T-cells have been implicated in the underlying cause of disease process, as have genetic factors. In this article, we critically reviewed findings, identified gaps in knowledge and suggested future directions for further investigation to identify targets and develop better therapeutic approaches. Expert commentary: Impaired gastric accommodation, slow gastric emptying, and increased visceral sensitivity have long been thought of as main causal factors of FD. However, more recent identification of eosinophilic degranulation and recruitment of T cells that induce mild duodenal inflammation are giving rise to new insights into immune-mediated pathophysiology. These insights offer promising avenues to explore for immune-mediated therapy in the future.

UR - http://www.scopus.com/inward/record.url?scp=85054625424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054625424&partnerID=8YFLogxK

U2 - 10.1080/1744666X.2018.1524756

DO - 10.1080/1744666X.2018.1524756

M3 - Review article

C2 - 30235962

AN - SCOPUS:85054625424

VL - 14

SP - 831

EP - 840

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 10

ER -